Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2015 - 20205

Settings

Has files: NoSubject: search.filters.subject.Prostate

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    The Impact of Hypoxemia on Serum Total and Free Prostate-Specific Antigen Levels in Patients with Chronic Obstructive Pulmonary Disease
    (2015) Ozge, Cengiz; Bozlu, Murat; Ozgur, Eylem Sercan; Tek, Mesut; Tunckiran, Ahmet; Muslu, Necati; Ilvan, Ahmet; 0000-0001-7303-7064; 25837435; V-6440-2019
    Prostate-specific antigen (PSA) is the most important biochemical marker in the diagnosis and follow-up of patients with prostate cancer. In recent years, a relationship between PSA levels and hypoxic conditions has been described. However, no study has investigated the PSA levels in patients with chronic obstructive pulmonary disease (COPD). The aim of the present study was to investigate the impact of hypoxemia on serum total (tPSA) and free PSA (fPSA) levels in patients with COPD. Between January 2010 and January 2014, 95 male patients who hospitalized for acute exacerbations of COPD and 80 control subjects were enrolled in the study. Serum tPSA and fPSA levels and f/tPSA ratios were determined in all patients on the first day of hospitalization (exacerbation) and 7 days after the treatment (stable state). Statistical analysis included paired t test and Mann-Whitney U test. No statistically significant differences were found between COPD and control groups with regard to the baseline characteristics, except for smoking status. The levels of serum tPSA and fPSA during exacerbation of COPD were significantly higher than the levels of the stable period (p < 0.01), whereas f/tPSA ratio did not change (p > 0.05). Hypoxemia during acute exacerbation of COPD can cause a rise in serum tPSA and fPSA levels, but f/tPSA ratio is not affected. Acute exacerbation of COPD may be added to list of the events in which PSA measurements must be interpreted with caution.
  • No Thumbnail Available
    Item
    Metachronous Prostate Metastasis of Renal Cell Carcinoma: Case Report and Review of the Literature
    (2016) Guler, Ozan Cem; Bal, Nebil; Onal, Cem; https://orcid.org/0000-0001-6908-3412; https://orcid.org/0000-0002-2742-9021; 26739102; AAC-5654-2020; HOC-5611-2023
    Secondary tumors of the prostate are very rare, and only a few reports of prostate metastasis originating from renal cell carcinoma (RCC) have been published. The reported 5-year survival rate has been approximately 35% for patients who underwent nephrectomy and surgical resection of a solitary metastasis. Immunohistochemical analysis showed that CD10 and vimentin positivity were helpful for distinguishing clear cell RCC from other renal tumors. We report a case with delayed metachronous metastasis of RCC to the prostate, which clinically mimicked benign prostatic hyperplasia or prostate cancer, treated with transurethral resection and palliative radiotherapy. (C) 2016 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    Dosimetric Analysis of Testicular Doses in Prostate Intensity-Modulated and Volumetric-Modulated Arc Radiation Therapy at Different Energy Levels
    (2016) Onal, Cem; ArsIan, Gungor; Dolek, Yemliha; Efe, Esma; 0000-0002-2742-9021; 27623736; D-5195-2014
    The aim of this study is to evaluate the incidental testicular doses during prostate radiation therapy with intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc radiotherapy (VMAT) at different energies. Dosimetric data of 15 patients with intermediate-risk prostate cancer who were treated with radiotherapy were analyzed. The prescribed dose was 78 Gy in 39 fractions. Dosimetric analysis compared testicular doses generated by 7-field intensity-modulated radiotherapy and volumetric modulated arc radiotherapy with a single arc at 6, 10, and 15 MV energy levels. Testicular doses calculated from the treatment planning system and doses measured from the detectors were analyzed. Mean testicular doses from the intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy per fraction calculated in the treatment planning system were 16.3 +/- 10.3 cGy vs 21.5 +/- 11.2 cGy (p = 0.03) at 6 MV, 13.4 +/- 10.4 cGy vs 17.8 +/- 10.7 cGy (p = 0.04) at 10 MV, and 10.6 +/- 8.5 cGy vs 14.5 +/- 8.6 cGy (p = 0.03) at 15 MV, respectively. Mean scattered testicular doses in the phantom measurements were 99.5 +/- 17.2 cGy, 118.7 +/- 16.4 cGy, and 193.9 +/- 14.5 cGy at 6, 10, and 15 MV, respectively, in the intensity-modulated radiotherapy plans. In the volumetric-modulated arc radiotherapy plans, corresponding testicular doses per course were 90.4 +/- 16.3 cGy, 103.6 +/- 16.4 cGy, and 139.3 +/- 14.6 cGy at 6, 10, and 15 MV, respectively. In conclusions, this study was the first to measure the incidental testicular doses by intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy plans at different energy levels during prostate-only irradiation. Higher photon energy and volumetric-modulated arc radiotherapy plans resulted in higher incidental testicular doses compared with lower photon energy and intensity-modulated radiotherapy plans. (C) 2016 American Association of Medical Dosimetrists.
  • No Thumbnail Available
    Item
    Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma
    (2020) Atilgan, Alev Ok; Ozdemir, B. Handan; Akcay, Eda Yilmaz; Tepeoglu, Merih; Borcek, Pelin; Dirim, Ayhan; 0000-0002-7528-3557; 0000-0001-8595-8880; 0000-0002-9894-8005; 0000-0001-6831-9585; 0000-0003-2898-485X; 32106037; X-8540-2019; AAK-3333-2021; AAK-5222-2021; AAK-1960-2021; AAJ-5689-2021
    Focal adhesion kinase (FAK), a member of the non-receptor cytoplasmic tyrosine kinase family, is associated with the development and progression of cancer. Matrix metalloproteinase-9 (MMP-9) is directly involved in the degradation of the extracellular matrix, and basement membrane components promote cancer cell migration and invasion. There is a functional interaction among FAK, MMP-9 and vascular endothelial growth factor (VEGF), which leads to enhanced cancer angiogenesis, cancer cell invasion and progression of malignancy. FAK, MMP-9, VEGF and CD34-positive microvessel density (MVD) were examined in 100 patients with prostate adenocarcinoma using immunohistochemistry. The relationship among these proteins and their impact on angiogenesis and clinicopathological parameters were also evaluated. The FAK expression was found to be positively correlated with the Gleason score, WHO grade group, tumour stage, extracapsular extension and perineural invasion. The MMP-9 expression was positively correlated with the WHO grade group, tumour stage, extracapsular extension, positive surgical margin and lymphovascular and perineural invasion. The FAK expression was also positively correlated with MMP-9 expression and MVD. However, no correlation between FAK and VEGF expression was identified. The MMP-9 expression was positively correlated with FAK expression and MVD. Strong MMP-9 expression was associated with shorter disease-free survival. These results suggest that strong MMP-9 and FAK expressions play an essential role in the progression of prostate adenocarcinoma. Further investigations should be conducted to determine the importance of these proteins as therapeutic targets for patients with prostate adenocarcinomas.
  • No Thumbnail Available
    Item
    Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    (2019) Yildirim, Berna Akkus; Onal, Cem; Kose, Fatih; Oymak, Ezgi; Sedef, Ali Murat; Besen, Ali Ayberk; Aksoy, Sercan; Guler, Ozan Cem; Sumbul, Ahmet Taner; Mualloglu, Sadik; Mertsoylu, Huseyin; Ozyigit, Gokhan; 30701292
    Purpose To evaluate the potential benefit of curative radiotherapy (RT) to the primary tumor in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone. Materials and methods The clinical parameters of 106 mCRPC patients treated with abiraterone were retrospectively evaluated. Patients were either oligometastatic (<= 5 metastases) at diagnosis or became oligometastatic after the systemic treatment was analyzed. Local RT to the primary tumor and pelvic lymphatics was delivered in 44 patients (41%), and 62 patients (59%) did not have RT to the primary tumor. After propensity match analysis, a total of 92 patients were analyzed. Resultsn Median follow-up time was 14.2 months (range: 2.3-54.9 months). Median overall survival (OS) was higher in patients treated with local RT to the primary tumor than in those treated without local RT with borderline significance (24.1 vs. 21.4 months; p=0.08). Local RT to the prostate and pelvic lymphatics significantly diminished the local recurrence rate (16 patients, 31% vs. 2 patients, 5%; p=0.003). In multivariate analysis, the prostate specific antigen (PSA) response >= 50% of the baseline obtained 3 weeks after abiraterone therapy was the only significant prognostic factor for better OS and progression-free survival (PFS). Patients treated with primary RT to the prostate had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT. Conclusions Local prostate RT significantly improved OS and local control in mCRPC patients treated with abiraterone. The patients treated with primary RT had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT.